| Literature DB >> 30288096 |
Do-Hyeong Kim1, Namo Kim1, Jae Hoon Lee1, Minju Jo1, Yong Seon Choi1.
Abstract
BACKGROUND: Children undergoing major orthopedic surgery of the lower extremities can experience severe postoperative pain; yet, the ideal postoperative pain management strategy is unknown. Thus, in this patient population, we investigated the effect of intraoperative epidural infusion of local anesthetic on acute postoperative pain and analgesic consumption. PATIENTS AND METHODS: Patients (N=50, 3-12 years) randomly received either ropivacaine 0.15% (preemptive group) or normal saline (control group) as an initial bolus of 0.2 mL/kg, followed by continuous infusion of 0.15 mL/kg/h throughout surgery. Following surgery, patient-controlled epidural analgesia with ropivacaine 0.1% was provided. The main study outcomes were the revised Face, Legs, Activity, Cry, and Consolability pain scores, epidural ropivacaine consumption, and additional analgesic requirements during the first 48 hours postoperatively.Entities:
Keywords: epidural analgesia; orthopedics; pediatrics; postoperative analgesia
Year: 2018 PMID: 30288096 PMCID: PMC6162994 DOI: 10.2147/JPR.S175169
Source DB: PubMed Journal: J Pain Res ISSN: 1178-7090 Impact factor: 3.133
Figure 1Flow diagram of patient selection.
Abbreviation: ICU, intensive care unit.
Patient characteristics and perioperative details
| Preemptive (n=23) | Control (n=24) | ||
|---|---|---|---|
|
| |||
| Female | 12 (52.2) | 12 (50.0) | 0.882 |
| Age (years) | 10.0±1.7 | 9.3±2.5 | 0.300 |
| Height (cm) | 133.4±14.8 | 128.7±18.4 | 0.370 |
| Weight (kg) | 31.1±9.4 | 29.5±11.1 | 0.606 |
| BMI (kg/m2) | 17.1±3.0 | 17.3±3.9 | 0.858 |
| Previous surgery on the lower limbs | 9 (39.1) | 8 (33.3) | 0.679 |
| Diagnosis | >0.999 | ||
| Cerebral palsy | 21 (91.3) | 21 (87.5) | |
| Others | 2 (8.7) | 3 (12.5) | |
| Surgical procedure | (n=46 legs) | (n=48 legs) | 0.447 |
| Pelvic osteotomy | 11 (24.1) | 15 (31.3) | |
| Femur osteotomy | 32 (69.6) | 37 (77.1) | |
| Tibial osteotomy | 5 (10.9) | 9 (18.8) | |
| Foot bony procedure | 10 (21.7) | 6 (12.5) | |
| Capsulotomy of hip | 1 (2.2) | 1 (2.1) | |
| Open reduction of hip dislocation | 5 (10.9) | 8 (16.7) | |
| Epiphysiodesis (femur or tibia tuberosity) | 9 (19.6) | 11 (22.9) | |
| Psoas lengthening | 11 (23.9) | 4 (8.3) | |
| Rectus femoris tenotomy | 1 (2.2) | 0 (0.0) | |
| Adductor tenotomy | 14 (30.4) | 26 (54.2) | |
| Medial hamstring lengthening | 5 (10.9) | 10 (20.8) | |
| Patella tendon advancement | 16 (34.8) | 17 (35.4) | |
| Tibialis anterior transfer | 2 (4.3) | 1 (2.1) | |
| Tibialis posterior interventions | 3 (6.5) | 1 (2.1) | |
| Calf muscle lengthening | 10 (21.7) | 14 (29.2) | |
| Tendon achilles lengthening | 10 (21.7) | 5 (10.4) | |
| Foot tendon interventions | 7 (15.2) | 9 (18.8) | |
| Amount of intraoperative ropivacaine (mg/kg) | 1.01±0.3 | – | – |
| Intraoperative blood loss (mL) | 200.0 (100.0–350.0) | 250.0 (200.0–387.5) | 0.198 |
| Total dose of ephedrine (mg) | 0.0 (0.0–4.0) | 0.0 (0.0–1.8) | 0.520 |
| Total dose of phenylephrine (μg) | 0.0 (0.0–250.0) | 0.0 (0.0–350.0) | 0.861 |
| Operation time (minutes) | 269.3±92.6 | 303.3±126.0 | 0.299 |
| Anesthesia time (minutes) | 334.8±102.6 | 367.3±120.3 | 0.325 |
| Length of PACU stay (minutes) | 45.0 (40.0–50.0) | 40.0 (40.0–50.0) | 0.440 |
Notes: Data are presented as mean±SD, median (interquartile range), or number of patients (%).
Femur osteotomy: femoral derotational osteotomy, femoral varizationderotational osteotomy, or distal femoral extension and shortening osteotomy.
Abbreviation: PACU, postanesthesia care unit.
Postoperative pain scores determined using the r-FLACC pain scale
| Preemptive (n=23) | Control (n=24) | Median difference (95% CI) | ||
|---|---|---|---|---|
|
| ||||
| r-FLACC | 0.035 | |||
| PACU | 0.0 (0.0–1.0) | 1.5 (1.0–2.5) | −1.0 (−2.0 to −1.0) | 0.001 |
| 6 hours | 1.0 (0.0–2.0) | 3.0 (2.0–4.0) | −2.0 (−3.0 to −1.0) | 0.005 |
| 12 hours | 1.0 (1.0–3.0) | 2.0 (1.0–3.0) | 0.0 (−1.0 to 0.0) | >0.999 |
| 24 hours | 1.0 (0.0–2.0) | 2.0 (1.0–3.0) | −1.0 (−1.0 to 0.0) | 0.692 |
| 48 hours | 0.0 (0.0–1.0) | 1.0 (0.5–2.0) | −1.0 (−1.0 to 0.0) | 0.351 |
Notes: Data are presented as median (interquartile range).
P-value of the group-by-time interaction in the nonparametric mixed model.
Abbreviations: PACU, postanesthesia care unit; r-FLACC, revised Face, Legs, Activity, Cry, and Consolability.
Consumption of epidural ropivacaine by patient-controlled analgesia and additional analgesic requirements
| Preemptive (n=23) | Control (n=24) | Mean or median difference (95% CI) | ||
|---|---|---|---|---|
| Amount of ropivacaine given as boluses (mg/kg/h) | 0.781 | |||
| 0–6 hours | 0.07±0.03 | 0.08±0.04 | −0.02 (−0.04 to 0.01) | 0.512 |
| 6–12 hours | 0.05±0.05 | 0.07±0.04 | −0.01 (−0.04 to 0.01) | >0.999 |
| 12–24 hours | 0.07±0.04 | 0.08±0.04 | −0.01 (−0.03 to 0.01) | >0.999 |
| 24–48 hours | 0.05±0.04 | 0.06±0.04 | −0.00 (−0.03 to 0.02) | >0.999 |
|
| ||||
| Amount of ropivacaine given as boluses plus background infusion (mg/kg/h) | 0.892 | |||
|
| ||||
| 0–6 hours | 0.12±0.03 | 0.13±0.04 | −0.02 (−0.04 to −0.01) | 0.582 |
| 6–12 hours | 0.10±0.05 | 0.12±0.04 | −0.01 (−0.04 to 0.01) | >0.999 |
| 12–24 hours | 0.12±0.04 | 0.12±0.04 | −0.01 (−0.03 to 0.01) | >0.999 |
| 24–48 hours | 0.10±0.04 | 0.11±0.04 | −0.01 (−0.03 to 0.02) | >0.999 |
|
| ||||
| Cumulative dose of ropivacaine given as boluses (mg/kg) | 0.804 | |||
|
| ||||
| ~6 hours | 0.48±0.23 | 0.59±0.27 | −0.11 (−0.26 to 0.04) | 0.566 |
| ~12 hours | 0.80±0.47 | 0.98±0.45 | −0.18 (−0.45 to 0.09) | 0.732 |
| ~24 hours | 1.60±0.93 | 1.90±0.78 | −0.30 (−0.81 to 0.20) | 0.928 |
| ~48 hours | 2.84±1.63 | 3.24±1.37 | −0.40 (−1.28 to 0.49) | >0.999 |
|
| ||||
| Cumulative dose of ropivacaine given as boluses plus background infusion (mg/kg) | 0.816 | |||
|
| ||||
| ~6 hours | 0.83±0.23 | 0.93±0.27 | −0.10 (−0.25 to 0.05) | 0.693 |
| ~12 hours | 1.45±0.48 | 1.63±0.45 | −0.18 (−0.45 to 0.10) | 0.822 |
| ~24 hours | 2.85±0.94 | 3.14±0.78 | −0.29 (−0.80 to 0.22) | >0.999 |
| ~48 hours | 5.24±1.66 | 5.66±1.37 | −0.42 (−1.31 to 0.47) | >0.999 |
|
| ||||
| Patients receiving rescue analgesics | 0.380 | |||
|
| ||||
| 0–6 hours | 4 (17.4) | 7 (29.1) | – | >0.999 |
| 6–12 hours | 10 (43.5) | 9 (37.5) | – | >0.999 |
| 12–24 hours | 12 (52.2) | 10 (41.7) | – | >0.999 |
| 24–48 hours | 10 (43.5) | 12 (50.0) | – | >0.999 |
|
| ||||
| Amount of rescue analgesics converted into equianalgesic doses of morphine (mg) | 0.261 | |||
|
| ||||
| 0–6 hours | 0.00 (0.00–0.00) | 0.00 (0.00–0.03) | 0.00 (0.00–0.00) | >0.999 |
| 6–12 hours | 0.00 (0.00–0.03) | 0.00 (0.00–0.03) | 0.00 (0.00–0.00) | >0.999 |
| 12–24 hours | 0.03 (0.00–0.03) | 0.00 (0.00–0.03) | 0.00 (0.00–0.03) | >0.999 |
| 24–48 hours | 0.00 (0.00–0.03) | 0.02 (0.00–0.03) | 0.00 (−0.03 to 0.00) | >0.999 |
Notes: Data are presented as mean±SD, median (interquartile range), or number of patients (%).
P-value of the group-by-time interaction in the linear mixed model.
P-value of the group-by-time interaction in the analysis using generalized estimation equation.
P-value of the group-by-time interaction in the nonparametric mixed model.
Figure 2Perioperative hemodynamic variables.
Notes: (A) Mean arterial pressure did not significantly differ between treatment groups at any time point. (B) Heart rate was significantly lower for the preemptive treatment group relative to control group between T1 and T3. All values are mean±SD. *P<0.05 vs control group. T0, 5 minutes after intubation (baseline); T1, 5 minutes after skin incision; T2, 1 hour after skin incision; T3, immediately after skin closure; T4, immediately after extubation; T5, 30 minutes after postanesthesia care unit admission.
Frequency of adverse events
| Preemptive (n=23) | Control (n=24) | ||
|---|---|---|---|
|
| |||
| PONV | 11 (47.8) | 9 (37.5) | 0.474 |
| Temporary discontinuation of PCA | 3 (13.0) | 1 (4.2) | 0.348 |
| Urinary retention | 4 (17.4) | 1 (4.2) | 0.188 |
| Transient motor blockade | 1 (4.3) | 3 (12.5) | 0.609 |
| Headache | 1 (4.3) | 0 (0.0) | 0.489 |
Note: Data are presented as number of patients (%).
Abbreviations: PCA, patient-controlled analgesia; PONV, postoperative nausea and vomiting.